New hope for advanced colorectal cancer: targeted drug M9140 enters early trial
NCT ID NCT06806046
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 39 times
Summary
This early-phase study tests an experimental drug called M9140 in 12 Chinese patients with advanced colorectal cancer that has not responded to standard treatments. The drug works like a guided missile, delivering chemotherapy directly to cancer cells that carry a specific marker (CEACAM5). The main goals are to check safety and see if the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Cancer Hospital
Beijing, China
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
-
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.